

 **Once-daily**  
**Pr Envarsus® PA**  
(tacrolimus prolonged-release tablets)

TCS

## A once-daily prolonged-release tacrolimus tablet\*

ENVARUSUS® PA (tacrolimus prolonged-release tablets) is indicated for the prophylaxis of organ rejection in adult allogenic kidney or liver transplant patients in combination with other immunosuppressants.

### A prolonged-release tacrolimus formulation that is unique to ENVARUSUS® PA<sup>†</sup>

The ENVARUSUS® PA formulation prolongs the absorption and increases the delivery of tacrolimus into the blood when compared to other tacrolimus formulations.<sup>†</sup>

Please consult the Product Monograph and the Dear Healthcare Professional Letter on inadvertent switching between different tacrolimus oral formulations, which could lead to graft rejection and other adverse reactions, available at <https://www.envarsus.ca/link-en> for important information on:

- Most serious warnings and precautions on serious infections and malignancies that may lead to hospitalization or death, prescriber restrictions, and patient management requirements.
- Other relevant warnings and precautions on being not interchangeable or substitutable on an equal dose basis with other existing tacrolimus-containing medicinal products; lactose, patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption; CYP3A4 inducers and inhibitors; lymphomas and other malignancies, particularly of the skin; post-transplant lymphoproliferative disorder (PTLD), associated with Epstein-Barr Virus (EBV); heart failure and ventricular hypertrophy or hypertrophy of the septum; prolonged QT/QTc interval, hypertension; gastrointestinal perforation; episodes of diarrhea; pure red cell aplasia and leukopenia; new-onset diabetes mellitus; bacterial, viral, fungal, and protozoal infections, including opportunistic infections; neurotoxicities; acute or chronic nephrotoxicity; hyperkalemia; renal insufficiency; pregnant and breastfeeding women; geriatrics.
- Adverse reactions, interactions, dosing, and conditions of clinical use that have not been discussed in this piece.

The Product Monograph is also available by calling us at 1-888-867-7426.

\*Please see Product Monograph for complete dosing and administration information.  
<sup>†</sup>Comparative clinical significance has not been established.

**REFERENCE:**  
ENVARUSUS® PA Product Monograph. June 16, 2020.



ENVARUSUS® is a registered trademark of Veloxis Pharmaceuticals A/S.  
© 2020 Paladin Labs. Québec

9500622

